130 related articles for article (PubMed ID: 31762274)
1. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Krieger V; Hamacher A; Cao F; Stenzel K; Gertzen CGW; Schäker-Hübner L; Kurz T; Gohlke H; Dekker FJ; Kassack MU; Hansen FK
J Med Chem; 2019 Dec; 62(24):11260-11279. PubMed ID: 31762274
[TBL] [Abstract][Full Text] [Related]
2. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
[TBL] [Abstract][Full Text] [Related]
3. Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Asfaha Y; Schrenk C; Alves Avelar LA; Lange F; Wang C; Bandolik JJ; Hamacher A; Kassack MU; Kurz T
Bioorg Med Chem; 2020 Jan; 28(1):115108. PubMed ID: 31787463
[TBL] [Abstract][Full Text] [Related]
4. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
5. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
[TBL] [Abstract][Full Text] [Related]
6. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Stenzel K; Hamacher A; Hansen FK; Gertzen CGW; Senger J; Marquardt V; Marek L; Marek M; Romier C; Remke M; Jung M; Gohlke H; Kassack MU; Kurz T
J Med Chem; 2017 Jul; 60(13):5334-5348. PubMed ID: 28581289
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
[TBL] [Abstract][Full Text] [Related]
8. Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors.
Diedrich D; Hamacher A; Gertzen CG; Alves Avelar LA; Reiss GJ; Kurz T; Gohlke H; Kassack MU; Hansen FK
Chem Commun (Camb); 2016 Feb; 52(15):3219-22. PubMed ID: 26810607
[TBL] [Abstract][Full Text] [Related]
9. Priming with HDAC Inhibitors Sensitizes Ovarian Cancer Cells to Treatment with Cisplatin and HSP90 Inhibitors.
Rodrigues Moita AJ; Bandolik JJ; Hansen FK; Kurz T; Hamacher A; Kassack MU
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167494
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
[TBL] [Abstract][Full Text] [Related]
12. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
[TBL] [Abstract][Full Text] [Related]
13. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model.
Taylan E; Zayou F; Murali R; Karlan BY; Pandol SJ; Edderkaoui M; Orsulic S
Gynecol Oncol; 2020 Oct; 159(1):277-284. PubMed ID: 32698955
[TBL] [Abstract][Full Text] [Related]
15. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
16. Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.
Schäker-Hübner L; Haschemi R; Büch T; Kraft FB; Brumme B; Schöler A; Jenke R; Meiler J; Aigner A; Bendas G; Hansen FK
ChemMedChem; 2022 May; 17(9):e202100755. PubMed ID: 35073610
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
[TBL] [Abstract][Full Text] [Related]
18. Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer.
Sun Y; Bao X; Ren Y; Jia L; Zou S; Han J; Zhao M; Han M; Li H; Hua Q; Fang Y; Yang J; Wu C; Chen G; Wang L
Cell Death Dis; 2019 May; 10(6):400. PubMed ID: 31127087
[TBL] [Abstract][Full Text] [Related]
19. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Yu C; He F; Qu Y; Zhang Q; Lv J; Zhang X; Xu A; Miao P; Wu J
Bioorg Med Chem; 2018 May; 26(8):1859-1868. PubMed ID: 29500131
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]